|Articles|June 25, 2020
Episode 59: Using Tau to Target Alzheimer’s
Author(s)Christen Harm, Elaine Quilici
Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.
Advertisement
Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Pharmaceutical Executive Magazine
·
Episode 59: Using Tau to Target Alzheimer’s
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharma and MedTech Rarely Collide. That Might Be the Biggest Miss in Healthcare
2
Insilico Medicine Enters $120 Million Drug Development Collaboration with Qilu Pharmaceuticals to Advance Cardiometabolic Therapies
3
Seamless Therapeutics Enters $1.12 Billion Global Research Collaboration with Eli Lilly to Develop Therapeutics for Hearing Loss
4
Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics
5